267 related articles for article (PubMed ID: 24561662)
1. Homogeneous low-molecular-weight heparins with reversible anticoagulant activity.
Xu Y; Cai C; Chandarajoti K; Hsieh PH; Li L; Pham TQ; Sparkenbaugh EM; Sheng J; Key NS; Pawlinski R; Harris EN; Linhardt RJ; Liu J
Nat Chem Biol; 2014 Apr; 10(4):248-50. PubMed ID: 24561662
[TBL] [Abstract][Full Text] [Related]
2. In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative.
Kuziej J; Litinas E; Hoppensteadt DA; Liu D; Walenga JM; Fareed J; Jeske W
Clin Appl Thromb Hemost; 2010 Aug; 16(4):377-86. PubMed ID: 20460347
[TBL] [Abstract][Full Text] [Related]
3. Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins.
Xu Y; Masuko S; Takieddin M; Xu H; Liu R; Jing J; Mousa SA; Linhardt RJ; Liu J
Science; 2011 Oct; 334(6055):498-501. PubMed ID: 22034431
[TBL] [Abstract][Full Text] [Related]
4. Protamine neutralisation of low molecular weight heparins and their oligosaccharide components.
Schroeder M; Hogwood J; Gray E; Mulloy B; Hackett AM; Johansen KB
Anal Bioanal Chem; 2011 Jan; 399(2):763-71. PubMed ID: 20922518
[TBL] [Abstract][Full Text] [Related]
5. The design and synthesis of new synthetic low-molecular-weight heparins.
Chandarajoti K; Liu J; Pawlinski R
J Thromb Haemost; 2016 Jun; 14(6):1135-45. PubMed ID: 26990516
[TBL] [Abstract][Full Text] [Related]
6. Preparation and evaluation a new generation of low molecular weight heparin.
Zhao D; Sang Q; Cui H
Biomed Pharmacother; 2016 Apr; 79():194-200. PubMed ID: 27044828
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of low-molecular-weight heparin reversal by platelet factor 4.
Fiore MM; Mackie IM
Thromb Res; 2009 May; 124(1):149-55. PubMed ID: 19195682
[TBL] [Abstract][Full Text] [Related]
8. Neutralization of the anticoagulant activity of low molecular weight heparin LU 47311 (Clivarin) in man by protamine chloride.
Andrassy K; Eschenfelder V; Weber E
Thromb Res; 1994 Jan; 73(2):85-93. PubMed ID: 8171416
[TBL] [Abstract][Full Text] [Related]
9. Chemoenzymatic synthesis of the next generation of ultralow MW heparin therapeutics.
Masuko S; Linhardt RJ
Future Med Chem; 2012 Mar; 4(3):289-96. PubMed ID: 22393937
[TBL] [Abstract][Full Text] [Related]
10. Heparin-Binding Copolymer as a Complete Antidote for Low-Molecular-Weight Heparins in Rats.
Kalaska B; Miklosz J; Kamiński K; Swieton J; Jakimczuk A; Yusa SI; Pawlak D; Nowakowska M; Szczubiałka K; Mogielnicki A
J Pharmacol Exp Ther; 2020 Apr; 373(1):51-61. PubMed ID: 31937564
[TBL] [Abstract][Full Text] [Related]
11. Neutralization of enoxaparine-induced bleeding by protamine sulfate.
Van Ryn-McKenna J; Cai L; Ofosu FA; Hirsh J; Buchanan MR
Thromb Haemost; 1990 Apr; 63(2):271-4. PubMed ID: 2163553
[TBL] [Abstract][Full Text] [Related]
12. Rational design of low-molecular weight heparins with improved in vivo activity.
Sundaram M; Qi Y; Shriver Z; Liu D; Zhao G; Venkataraman G; Langer R; Sasisekharan R
Proc Natl Acad Sci U S A; 2003 Jan; 100(2):651-6. PubMed ID: 12525684
[TBL] [Abstract][Full Text] [Related]
13. Reversal of low-molecular-weight heparin anticoagulation by synthetic protamine analogues.
Wakefield TW; Andrews PC; Wrobleski SK; Kadell AM; Fazzalari A; Nichol BJ; Vanderkooi T; Stanley JC
J Surg Res; 1994 Jun; 56(6):586-93. PubMed ID: 8015315
[TBL] [Abstract][Full Text] [Related]
14. A [+18RGD] protamine variant for nontoxic and effective reversal of conventional heparin and low-molecular-weight heparin anticoagulation.
Wakefield TW; Andrews PC; Wrobleski SK; Kadell AM; Tejwani S; Hulin MS; Stanley JC
J Surg Res; 1996 Jun; 63(1):280-6. PubMed ID: 8661211
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of a N'-alkylamine anticoagulant active low-molecular-mass heparin for radioactive and fluorescent labeling.
Malsch R; Guerrini M; Torri G; Löhr G; Casu B; Harenberg J
Anal Biochem; 1994 Mar; 217(2):255-64. PubMed ID: 8203754
[TBL] [Abstract][Full Text] [Related]
16. An update on heparins at the beginning of the new millennium.
Fareed J; Hoppensteadt DA; Bick RL
Semin Thromb Hemost; 2000; 26 Suppl 1():5-21. PubMed ID: 11011802
[TBL] [Abstract][Full Text] [Related]
17. Fragment profiling of low molecular weight heparins using reversed phase ion pair liquid chromatography-electrospray mass spectrometry.
Xu X; Li D; Chi L; Du X; Bai X; Chi L
Carbohydr Res; 2015 Apr; 407():26-33. PubMed ID: 25701653
[TBL] [Abstract][Full Text] [Related]
18. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.
Holst J; Lindblad B; Bergqvist D; Hedner U; Nordfang O; Ostergaard P
Thromb Res; 1997 May; 86(4):343-8. PubMed ID: 9187023
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological effects and clinical applications of ultra low molecular weight heparins.
Liu Z; Ji S; Sheng J; Wang F
Drug Discov Ther; 2014 Feb; 8(1):1-10. PubMed ID: 24647152
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo characterization of a reversible synthetic heparin analog.
Whelihan MF; Cooley B; Xu Y; Pawlinski R; Liu J; Key NS
Thromb Res; 2016 Feb; 138():121-129. PubMed ID: 26709038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
